Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Crano-cure inTreatment of Urinary Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 to 60 years with symptomatic acute urinary tract infection.~  * Willing to participate in the study~ * Non-pregnant adult females.~ * Clinical signs and symptoms of a UTI (e.g., dysuria, frequency, urgency to urinate, Burning sensations during urination, Hematuria, suprapubic pain) with onset of symptoms \< 72 hours prior to study entry.~ * One positive pre-treatment clean-catch midstream urine culture within 48 hours of enrollment in the study, defined as \> 105 CFU/mL.~ * Patients having all socioeconomic classes including lower, middle and higher.~ * In-vitro susceptibility testing of the uropathogen to test and control drug.~Exclusion Criteria:~* • Women who are pregnant, nursing, or not using a medically accepted, effective method of birth control. If an antimicrobial agent is to be studied for the treatment of UTI in pregnant women, this proposal should be justified, the risk/benefit expectations explained, and the issue presented to the division.~  * Three or more episodes of acute uncomplicated UTI in the past 12 months.~ * Patients with evidence of factors predisposing to the development of urinary tract infections, including calculi, stricture, primary renal disease (e.g., polycystic renal disease), or neurogenic bladder.~ * Patients with onset of symptoms 96 hours or more prior to entry.~ * Patients with a temperature \> 1010 F, flank pain, chills, or any other manifestations suggestive of upper urinary tract infection.~ * Patients with known or suspected hypersensitivity to the test or control drug.~ * Patients who received treatment with other antimicrobials within 48 hours prior to entry.~ * Patient suffering in chronic illness Diabetes mellitus, chronic liver diseases

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
- control group (Type: ACTIVE_COMPARATOR): No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).